Business
Taysha Gene Therapies Joins the Rare Disease Company Coalition
Joined an alliance of life science companies dedicated to rare disease therapy development to support advocacy for policies that will improve processes for
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nJoined an alliance of life science companies dedicated to rare disease therapy development to support advocacy for policies that will improve processes for timely and cost-effective delivery of treatments\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has joined the newly formed Rare Disease Company Coalition, a first-of-its-kind alignment of life sciences companies committed to discovering, developing and delivering rare disease treatments for the patients they collectively serve.\n\n“Taysha is honored to be a founding member of the Rare Disease Company Coalition,” said RA Session II, President, Founder and Chief Executive Officer of Taysha. “As we grow to become a leader in the development of gene therapies for the treatment of rare diseases, we have a responsibility to our community, especially to our patients and their families, to advocate for more effective policies and regulations that will encourage innovation around potentially life-saving therapies. We look forward to working with this impressive group of companies to drive awareness about the specific challenges of rare disease research and development and promote solutions that will support timely delivery of valuable treatments to patients.”\n\nAs an education and advocacy-focused coalition of companies, the shared goal of the Coalition is to inform policymakers of the unique circumstances of the rare disease company business model, specifically focusing on the unique circumstances involved in developing and bringing to market therapies for small and differentiated patient population sizes. The Coalition will advocate for policy and regulatory frameworks that account for and recognize the distinct considerations of life science companies operating in the rare disease space and the impact it has on delivering innovative therapies to the patients they serve.\n\nFounding members of the Coalition include:\n\n\nAcceleron Pharma\n\n\nAeglea BioTherapeutics\n\n\nAgios Pharmaceuticals\n\n\nAlnylam Pharmaceuticals\n\n\nHarmony Biosciences\n\n\nOrchard Therapeutics\n\n\nOrphazyme US, In...